Catalyst Pharmaceuticals Reports Third Quarter 2021 Financial Results
09 nov. 2021 16h14 HE
|
Catalyst Pharmaceuticals, Inc.
Continued Strong Financial and Operational Performance in the Third Quarter 2021FIRDAPSE® Revenue of $35.9 Million Increased 23.1% Compared to Third Quarter 2020Plans to Seek to Expand the U.S....
Catalyst Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 9, 2021
25 oct. 2021 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceuticals Receives Positive Decision from Appeals Court That Supports Orphan Drug Exclusivity for Firdapse® for LEMS
30 sept. 2021 12h08 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Catalyst Pharmaceuticals to Participate at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
17 sept. 2021 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
10 sept. 2021 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Catalyst Pharmaceuticals Appoints Mary Coleman as Vice President, Head of Investor Relations
16 août 2021 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate Update
09 août 2021 16h39 HE
|
Catalyst Pharmaceuticals, Inc.
-Q2 2021 Total Net Revenues of $36.4 Million Reflect Strong Quarter over Quarter Growth -Q2 2021 GAAP Net Income of $12.2 Million; Non-GAAP Net Income of $17.4 Million -$155.3...
Catalyst Pharmaceuticals to Hold Second Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, August 10th, 2021
26 juil. 2021 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., July 26, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceuticals Announces Issuance of U.S. Patent 11,060,128 a Method of Use Patent with Claims Covering Firdapse®
19 juil. 2021 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
New patent bolsters intellectual property protection for Firdapse®First in a family of four pending patents for Firdapse® to issue CORAL GABLES, Fla., July 19, 2021 (GLOBE NEWSWIRE) -- Catalyst...
Catalyst Pharmaceuticals Expands Leadership Team with Appointment of Preethi Sundaram, Ph.D. as Chief Product Development Officer
06 juil. 2021 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., July 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...